Trastuzumab Deruxtecan
- Product Name
- Trastuzumab Deruxtecan
- CAS No.
- 1826843-81-5
- Chemical Name
- Trastuzumab Deruxtecan
- Synonyms
- Enhertu;Trastuzumab Deruxtecan;Fam-trastuzumab deruxtecan;Trastuzumab deruxtecan (ADC);Trastuzumab deruxtecan (solution);Trastuzumab deruxtecan (anti-ERBB2);DS-8201a|||VRN-101099|||DS 8201|||T-DXd;Trastuzumab deruxtecan (DS-8201a, T-DXd)
- CBNumber
- CB18081028
- Molecular Formula
- N/A
- Formula Weight
- 0
- MOL File
- Mol file
Trastuzumab Deruxtecan Property
- storage temp.
- Solution, -20°C, 2 years
- solubility
- Soluble in acetonitrile
- form
- Solid
- color
- White to off-white
Trastuzumab Deruxtecan Chemical Properties,Usage,Production
Uses
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer[1][2].
Biological Activity
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC).
in vitro
Trastuzumab deruxtecan (1 pM-10 nM; 5 days) inhibits the growth of HER2‐positive KPL‐4 cells, with an IC 50 of 109.7 pM.
Trastuzumab deruxtecan (10 nM; 5 days) shows bystander killing effects in HER2‐negative MDA‐MB‐468 cells.
in vivo
Trastuzumab deruxtecan (3 mg/kg; a single iv) shows antitumor activity against not only HER2‐positive tumors but also HER2‐negative tumors under the co‐inoculated condition.
References
[1] Kumagai K, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020 Dec;111(12):4636-4645. DOI:10.1111/cas.14686
[2] Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518. DOI:10.1177/1758835920986518
[3] Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46. DOI:10.1111/cas.12966
[4] Iwata TN, et, al. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS One. 2019 Oct 1;14(10):e0222280. DOI:10.1371/journal.pone.0222280
Trastuzumab Deruxtecan Preparation Products And Raw materials
Raw materials
Preparation Products
Trastuzumab Deruxtecan Suppliers
- Tel
- 027-027-16602739303 16602739303
- 673003916@qq.com
- Country
- China
- ProdList
- 2935
- Advantage
- 58
- Tel
- 021-021-52919136 17315815539
- 2804155403@qq.com
- Country
- China
- ProdList
- 180
- Advantage
- 58
- Tel
- 27-027-83314682 13554138826
- Fax
- +86 (27) 8331-4682
- whsrtech@vip.163.com
- Country
- China
- ProdList
- 246
- Advantage
- 62
- Tel
- 025-57798810
- Fax
- 025-57019371
- sales@sunlidabio.com
- Country
- China
- ProdList
- 3239
- Advantage
- 55
- Tel
- 18149758185
- sales-cpd@caerulumpharma.com
- Country
- China
- ProdList
- 3505
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- Fax
- 021-65675885
- info@efebio.com
- Country
- China
- ProdList
- 9803
- Advantage
- 58
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- +86-0551-62678551 +86-15056975894
- Fax
- 05512678551
- sales@hirisunpharm.com
- Country
- China
- ProdList
- 176
- Advantage
- 55
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- 0512-85557988 18662338937
- Fax
- 0512-85557182
- frank.wang@greature.com.cn
- Country
- China
- ProdList
- 147
- Advantage
- 58